Direct Medical Cost Analysis Of Ceftriaxone Vs Levofloxacine Therapy For Community Acquired Pneumonia Patient at The X Government Hospital NTB
Abstract
Pneumonia is a respiratory tract infection with the highest number of cases in Government Hospital X in NTB in 2018. The worst impact of pneumonia are death and high cost of health services risk. So management of costs is needed for effectively and efficiently. The therapeutic choice for community acquired pneumonia (CAP) used in X Hospital is ceftriaxone and levofloxacin which have a high price difference. This study aims to calculate the average direct medical costs in hospitalized CAP patients who use ceftriaxone and levofloxacin therapy at Government Hospital X in NTB in 2018.
This research type is quantitative analysis using secondary data that compares the average direct medical costs of two alternative treatments for CAP with the BPJS Kesehatan perspective. The cost component are cost of medicine, care, doctor, emergency room, accommodation, and laboratory. The number of samples was 65 patients.
The results showed: (1) The average direct medical costs using ceftriaxone was Rp.3.034.965, while levofloxacin was Rp.1.594.053; (2) There is significant difference in the average direct medical cost of Rp.1.440.912 perpatient; (3) Levofloxacin provide the lowest rupiah than ceftriaxone in community acquired pneumonia patients.
References
[2]. Kementerian Kesehatan RI, Riset Kesehatan Dasar, 2018.
[3]. Dahlan, Z., Buku Ajar Ilmu Penyakit Dalam Jilid II, Edisi IV. Jakarta: Pusat Penerbitan Departemen Ilmu Penyakit Dalam FKUI, 2007
[4]. Metlay, Joshua P., et al. “Diagnosis and Treatment of Adults with Community-Acquired Pneumonia. An Official Clinical Pratice Guideline of The American Thoracic Society and Infectious Diseases Society of America”. American Journal of Respiratory and Critical Care Medicine, Vol. 200, Issue 7, Ocotber 2019
[5]. Abegunde, D., “Inefficiencies due to Poor Access to and Irrational Use of Medicines to Treat Acute Respiratory Tract Infections in Children,” Geneva: World Health Organization (WHO), 2010
[6]. Bootman, J. L., Townsend, R. J., and McGhan, W. F., Principles of Pharmacoeconomics, 3rd Ed. USA: Harvey Whitney Book Company, 2005, pp. 1-18.
[7]. Bauer, T.T., Welte, T., Ernen, C., Schlosser, B.M., Waschke, I.T., Zecuw, J., Werninghaus, G.S., “Cost Analysis of Community Acquired Pneumonia From the Hospital Perspective”, Chest, 2005.
[8]. Nuraini, “Gambaran Pengobatan dan Analisis Biaya Terapi Pneumonia Pada Pasien Anak di Instalasi Rawat Inap RS ”X” Tahun 2011,”Surakarta: Naskah publikasi, Fakultas Farmasi Universitas Muhammadiyah Surakarta, 2012,.
[9]. Rahmawati, C., Nopitasari, B.L., dan Safitri, N,P.,“Gambaran Biaya Langsung Medis Penyakit Pneumonia Dengan Terapi Ceftriaxone di Rawat Inap Rumah Sakit Umum Daerah X di NTB Tahun 2018,”. Lumbung Farmasi Jurnal Ilmu Kefarmasian, Vol. 1 No.1, Januari 2020.
[10]. Lee, Mi Suk, et al. Guideline for Antibiotic Use in Adults with Community-Acquired Pneumonia. Infection & Chemotherapy Journal, Vol. 50 (2), June 2018
[11]. Puteri, Teti Dynaila, “Analisis Biaya Penggunaan Antibiotik Pada Pasien Pneumonia Di Instalasi Rawat Inap IRNA Anak RSUP Dr. M. Djamil Padang,” Padang: Naskah Publikasi. Program Pascasarjana Universitas Andalas, 2012.
[12]. Wulandari D.N, “Efektivitas Penggunaan Antibiotik Ceftriaxone Pada Pasien Pneumonia Dewasa Di Instalasi Rawat Inap RSUD Dr. Moewardi Surakarta Tahun 2014-2015,” Semarang: Naskah Publikasi Universitas Sebelas Maret, 2016.
[13]. Nursyafrisda, “Analisis Efektifitas Biaya Penggunaan Ceftriaxone dan Cefotaxime Pada Pasien Pneumonia Balita di Rawat Inap RSU Kab. Tanggerang,” Depok: Tesis Fakultas Kesehatan Masyarakat, 2010.
[14]. S. Wardhani TB,“Analisis Efektivitas Biaya Penggunaan Antibiotik Pada Pasien Pneumonia Komunitas Rawat Inap Di RSUD Kabupaten Cilacap Tahun 2008-2010,” Yogyakarta: Naskah Publikasi Farmasi FMIPA Universitas Islam Indonesia, 2011.
